Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Completed · Phase 3

Conditions studied: Opioid-Induced Constipation (OIC)

In brief

The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.

Key facts

Study ID

NCT01336205

Run by

AstraZeneca

People needed

844

Starts

2011-04-01

Expected to finish

2012-12-01

Last updated by the study team

2014-10-20

Who can join

Age: 18 and older, up to 84. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of written informed consent prior to any study-specific procedures.
• NEW PATIENTS ONLY: Self-reported active symptoms of OIC at screening (<3 SBMs/week and experiencing >1 reported symptom of hard/lumpy stools, straining, or sensation of incomplete evacuation/anorectal obstruction in at least 25% of the BMs over the previous 4 weeks); and Documented confirmed OIC (<3 SBMs/week on average over the 2-week OIC confirmation period.
• PATIENTS ENROLLING FROM OTHER NKTR-118 STUDIES: Receiving a stable maintenance opioid regimen consisting of a total daily dose of 30 mg to 1000 mg or oral morphine, or equianalgesic amount(s) of 1 or more opioid therapies.
• FOR PATIENTS RANDOMIZED TO RECEIVE NKTR-118: Willingness to stop all laxatives and other bowel regimens including prune juice and herbal products throughout the 52-week treatment period, and to use only bisacodyl as rescue medication if BM has not occurred within at least 72 hours of the last recorded BM.

You may not qualify if…

• Patients receiving Opioid regimen for treatment of pain related to cancer.
• History of cancer within 5 years from first study visit with the exception of basal cell cancer and squamous cell skin cancer.
• Medical conditions and treatments associated with diarrhea, intermittent loose stools, or constipation.
• Other issues related to the gastrointestinal tract that could impose a risk to the patient.
• Pregnancy or lactation.

Where it is running

• Research Site — Birmingham, Alabama, United States
• Research Site — Huntsville, Alabama, United States
• Research Site — Mobile, Alabama, United States
• Research Site — Pell City, Alabama, United States
• Research Site — Garden Grove, Arizona, United States
• Research Site — Goodyear, Arizona, United States
• Research Site — Mesa, Arizona, United States
• Research Site — Phoenix, Arizona, United States
• Research Site — Tucson, Arizona, United States
• Research Site — Tuscon, Arizona, United States
• Research Site — Jonesboro, Arkansas, United States
• Research Site — Little Rock, Arkansas, United States
• Research Site — North Little Rock, Arkansas, United States
• Research Site — Sherwood, Arkansas, United States
• Research Site — Arcadia, California, United States
• Research Site — Chino, California, United States
• Research Site — Encino, California, United States
• Research Site — Fremont, California, United States
• Research Site — Garden Grove, California, United States
• Research Site — Huntington Park, California, United States
• Research Site — La Mesa, California, United States
• Research Site — Laguna Hills, California, United States
• Research Site — Lakewood, California, United States
• Research Site — Long Beach, California, United States
• Research Site — Athens, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.